Summary of the results of frequency and distribution analyses of

En la tabla 2 se contrasta la periodicidad mínima recomendada por la guía del Reino Unido (7) y que se sugiere en la presente revisión para evaluar la tasa de filtración glomerular mediante la fórmula modificada de MDRD (47) (o en su defecto por la fórmula de Cockroft- Gault) a todo paciente adulto con diagnóstico de enfer- medad renal crónica:

Se define «estable» como un cambio en la tasa de filtración glomerular menor a 2 mL/min/1,73 m2 _{en un}

periodo de seis meses o más; y «progresiva» como un cambio en la tasa de filtración glomerular mayor a 2 mL/ min/1,73 m2 _{en un lapso de seis o más meses.}

Referencias

1. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35 (4) (Suppl 1): S117-31,.

2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41 (1): 1-12. 3. León Martínez F, Ordóñez IE, León García D. Deficiencies in the treatment of diabetic

patients that ended with renal failure. Acta Med Colomb 2007; 32 (2): 57-67. 4. Gómez RH, et al. Análisis de sobrevida en pacientes de diálisis Unidad Renal FVL

1992-2003, abstract Congreso Latinoamericano de Nefrología e Hipertensión Arterial. Punta del Este, 2004.

5. Enriquez J, et al. Survival of chronic dialysis: CAPD and hemodialysis, 10 year experience of a single Colombian center. Peritoneal Dialysis International 2005; 25 (suppl s1): s23,

6. Ministerio de la Protección Social – Programa de Apoyo a la Reforma de Salud. Enfermedad renal crónica. Guía para el manejo y modelo de prevención y control. Editorial Scripto Ltda, Bogotá, 2007. Disponible en: http:// www.minproteccionsocial.gov.co/VBeContent/library/documents/ DocNewsNo16253DocumentNo4298.pdf.

7. Royal College of Physicians and the Renal Association. Chronic kidney disease in adults -UK guidelines for identification, management and referral. Nephrol Dial Transplant 2006; 21 (7): 1776-1777.

8. Scottish intercollegiate guidelines network. Diagnosis and management of chronic kidney disease. Disponible en: http://www.sign.ac.uk/guidelines/fulltext/103/ index.html

9. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl 1): S1-S266.

10. López-Viñas C, Jaramillo AC, Jaimes JE, Muñoz JE, Murcia B, Sánchez C. Prevalencia de enfermedad renal y entidades asociadas: Una base para la promoción de la salud en la población de Simijaca. Revista de la Facultad de Medicina, Universidad El Bosque 10 (1): 63-70.

11. Asociación Colombiana de Nefrología e Hipertensión Arterial, 2005. 12. Gilbertson D, Solid C, Xue JL, Collins AJ. Projecting the U.S. ESRD population by

2030. US Renal Data System: Data presented at the 2003 American Society of Nephrology Annual Meeting. Disponible en: URL: http://www.usrds.org/2003/ pres/html/5U_ASN_projections _files/frame.htm

13. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new- onset kidney disease in a community-based population. JAMA 2004; 291: 844-850. 14. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al. Prevalence of kidney damage in australian adults: The AusDiab Kidney Study. J Am Soc Nephrol 2003; 14: S131-S138.

15. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16 (2): 489-95.

16. Briganti EM, Branley P, Chadban SJ, Shaw JE, McNeil JJ, Welborn TA, et al. Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab kidney study. Australian Diabetes, Obesity and Lifestyle Study. Am J Kidney Dis 2002; 40 (4): 704-12.

17. Ejerblad E, Fored CM, Lindblad P, Fryzek J, Dickman PW, Elinder CG, et al. Association between smoking and chronic renal failure in a nationwide population- based case-control Study. J Am Soc Nephrol 2004; 15: 2178-2185. 18. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular

disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004; 15: 1912-1919. 19. Perry HM, Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (4 Pt 1): 587-94.

20. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new- onset kidney disease in a community-based population. JAMA 2004;29 1: 844-850. 21. Roderick PJ, Atkins RJ, Smeeth L, Nitsch DM, Hubbard RB, Flectcher AE, et al. Detecting chronic kidney disease in older people; what are the implications? Age and Ageing 2008; 37 (2): 179-186.

22. Kurth T, Glynn RJ, Walker AM, Rexrode KM, Buring JE, Stampfer MJ, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003; 42 (2): 234-244.

23. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164 (14): 1519-24.

24. Agodoa LY, Francis ME, Eggers PW. Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults. Am J Kidney Dis 2008; 51 (4): 573- 83.

25. Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol 2006; 17: 2533- 2545.

26. Elsayed EF, Sarnak MJ, Tighiouart H, Griffith JL, Kurth T, Salem DN. Waist-to-hip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis 2008; 52 (1): 29-38.

27. Ejerblad E, Fored CM, LindbladP, Fryzek J, McLaughlin JK, Nyrén O. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-1702. 28. Foster MC, Hwang SJ, Larson MG, Lichtman JH, Parikh NI, Vasan RS, et al.

Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52 (1): 39-48. Epub 2008 Apr 28.

29. Fored CM, Ejerblad E, Fryzek JP, Lambe M, Lindblad P, Nyren O, et al. Socio- economic status and chronic renal failure: a population-based case-control study in Sweden. Nephrol Dial Transplant 2003; 18 (1): 82-8.

30. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D’Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000; 11 (8): 1439-48.

31. Aurell M, Svalander C, Wallin L, Alling C. Renal function and biopsy findings in patients on long-term lithium treatment. Kidney Int 1981; 20 (5): 663-70. 32. Bendz H, Aurell M, Lanke J. A historical cohort study of kidney damage in longterm

lithium patients: continued surveillance needed. Eur Psychiatry 2001; 16 (4): 199-206.

Tabla 2.

PERIODICIDAD PARA EL CONTROL DE LA TASA DE FILTRACIÓN GLOMERULAR Enfermedad renal crónica Guía del Reino Unido (7) Presente guía

Estado 1 Anual Anual

Estado 2 Anual Anual

Estado 3. Estable Anual Semestral

Estado 3. Diagnóstico reciente o curso progresivo Semestral Bimestral

Estado 4. Estable Semestral Bimestral

Estado 4. Diagnóstico reciente o curso progresivo Trimestral Mensual

33. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11: 614-621.

34. Russell NKI, Knight SR, Morris PJ. Cyclosporine. En: Morris PJ, Knechtle SJ. Kidney Transplantation. Saunders Elsevier, Philadelphia; 2008.

35. Ponticelli C, Banfi G, Moroni G. Systemic lupus erithematosus (clinical). In: Davidson AM, Cameron JS, Grunfeld JP, Ponticelli C, Ritz E, Winearls CG, Ypersele C. Oxford Textbook of Clinical Nephrology. Oxford University Press; 2005. p. 824-842. 36. Stegeman CA, Kallenberg CGM. Pathogenesis of angiitis. In: Davidson AM,

Cameron JS, Grunfeld JP, Ponticelli C, Ritz E, Winearls CG, Ypersele C. Oxford Textbook of Clinical Nephrology. Oxford University Press; 2005. p. 741-753. 37. Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU,

Bourgeois P, Deray G. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology 2000; 47: 350-354. 38. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al.; Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110 (6): 1376-84.

39. Freedman BI, Soucie JM, McClellan WM. Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 1997; 8 (12): 1942-5.

40. Jurkovitz C, Franch H, Shoham D, Bellenger J, McClellan W. Family members of patients treated for ESRD have high rates of undetected kidney disease. Am J Kidney Dis 2002; 40 (6): 1173-8.

41. Gambaro G, Favaro S, D’Angelo A. Risk for renal failure in nephrolithiasis. Am JKidney Dis 2001; 37 (2): 233-43.

42. Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30-48.

43. Packer M, Lee WH, Medina N, Yushak M, Kessler Pd. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Inter Med 1987; 106: 346-354.

44. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin- converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158: 26-32.

45. Palmer BF. Managing hyperkalemia caused by inhibitors of the rennin.angiotensin- aldosterone system. New Engl J Med 2004; 351: 585-592.

46. Hollenberg NK. ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and renin antagonists. En: Wilcox CS (ed): Therapy in nephrology and hypertension. Philadelphia: Saunders Elsevier; 2008. p. 601-609. 47. Levey AS, Greene T, Kusek JW, Beck GJ, Group. MS. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: 155A.